中樞神經系統治療市場規模、佔有率、成長分析，按疾病類型、按藥物類型、按藥物類別、按分銷管道、按地區 - 行業預測，2025 年至 2032 年

預計 2023 年全球中樞神經系統治療市場規模將達到 1,282.9 億美元，並從 2024 年的 1,363.7 億美元成長到 2032 年的 2,223.3 億美元，預測期內（2025-2032 年）的複合年成長率為 6.3%。

世界上越來越思覺失調症和阿茲海默症）的發病率激增。這一趨勢要求採取多學科治療方法，包括神經外科醫生、神經科和物理治療師，促進合作，為患者照護。神經科學的不斷進步正在推動創新治療方法的發展，包括手術技術、基因治療和神經影像技術。根據世界衛生組織 (WHO) 統計，全球有超過 10 億人受到影響，製藥公司正在透過投資新的中樞神經系統藥物來滿足尚未滿足的重大醫療需求。此外，學名藥的普及有望改善治療機會，特別是在中低收入國家，從而促進中樞神經系統藥物市場的成長和競爭的加劇。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 宏觀經濟指標
• 價值鏈分析
• 定價分析

中樞神經系統治療市場規模（依疾病類型）

• 市場概況
• 神經血管疾病
  • 出血性中風
  • 缺血性中風
  • 其他
• 神經退化性疾病
  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 其他
• 心理健康
  • 癲癇
  • 情緒障礙
  • 焦慮症
  • 其他
• 感染疾病
  • 腦膜炎
  • 腦炎
  • 其他
• 其他

中樞神經系統治療市場規模（依藥物類型）

• 市場概況
• 生物製藥
• 非生技藥品

中樞神經系統治療市場規模（依藥物類別）

• 市場概況
• 免疫調節藥物
• 干擾素
• 脫羧酶抑制劑
• 促效劑
• 抗憂鬱症
• 止痛藥
• 其他

中樞神經系統治療市場規模（按分銷管道）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

中樞神經系統治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Biogen Inc.（United States）
• Johnson & Johnson（United States）
• Novartis AG（Switzerland）
• UCB SA（Belgium）
• Takeda Pharmaceutical Company Ltd.（Japan）
• Pfizer Inc.（United States）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• Eli Lilly and Company（United States）
• Otsuka Holdings Co., Ltd.（Japan）
• Lundbeck A/S（Denmark）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• AstraZeneca plc（United Kingdom）
• Merck & Co., Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• Amgen Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• AbbVie Inc.（United States）
• Allergan plc（Ireland）
• Shionogi & Co., Ltd.（Japan）

結論和建議

Global Central Nervous System Treatment Market size was valued at USD 128.29 billion in 2023 and is poised to grow from USD 136.37 billion in 2024 to USD 222.33 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The global rise in sedentary and hectic lifestyles has resulted in a surge of chronic and central nervous system (CNS) disorders, such as schizophrenia and Alzheimer's disease. This trend has necessitated a multidisciplinary treatment approach involving neurosurgeons, neurologists, and physical therapists, fostering collaboration for comprehensive patient care. Ongoing advancements in neuroscience are driving the development of innovative treatments, including surgical techniques, gene therapies, and neuroimaging technologies. As the World Health Organization reports over 1 billion affected individuals worldwide, pharmaceutical companies are responding by investing in new CNS therapies to address significant unmet medical needs. Additionally, the availability of generic medications is enhancing treatment access, particularly in low- and middle-income countries, promising market growth and increased competition in CNS therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Central Nervous System Treatment Market Segmental Analysis

Global Central Nervous System Treatment Market is segmented by Disease Type, Drug Type, Drug Class, Distribution Channel and region. Based on Disease Type, the market is segmented into Neurovascular Diseases, Neurodegenerative Diseases, Mental Health, Infectious Diseases and Others. Based on Drug Type, the market is segmented into Biologics and Non-biologics. Based on Drug Class, the market is segmented into Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, Analgesics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Central Nervous System Treatment Market

The Global Central Nervous System Treatment market is being propelled by a notable increase in the incidence of mental health disorders and significant advancements in pipeline research. The rising global prevalence of neurological conditions such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease is a major factor in driving market expansion. Additionally, the aging population in many regions is contributing to the surge in Alzheimer's cases; the Alzheimer's Association reports over five million individuals currently affected, with projections reaching 14 million by 2050. Furthermore, the potential launch of new treatments for these conditions is expected to enhance healthcare access in developing nations, exemplified by Corbus Pharmaceuticals' ongoing Phase 3 clinical trial of Lenabasum for diffuse cutaneous systemic sclerosis. This combination of rising disease prevalence and innovative treatment options creates a robust foundation for growth in the sector.

Restraints in the Global Central Nervous System Treatment Market

The Global Central Nervous System Treatment market faces significant restraints primarily due to the high costs associated with drug development and complex regulatory requirements. Investment in research and development for therapies targeting CNS disorders is notably higher compared to other therapeutic areas. The specialized nature of CNS treatments mandates a high level of precision, but there is a scarcity of qualified medical professionals to conduct such work. Additionally, the lengthy drug approval process, which can span several years, complicates the timeline for bringing CNS drugs to market. Insufficient understanding of neuroscience may hinder timely approvals and delay the introduction of effective treatments for CNS disorders.

Market Trends of the Global Central Nervous System Treatment Market

The Global Central Nervous System (CNS) Treatment market is experiencing robust growth, driven by increasing investments in neuroscience research, drug development, and innovative therapeutic solutions. Rising incidences of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis are propelling demand for more effective treatments. Additionally, advancements in technology, including neuroimaging and biomarker discovery, are providing new avenues for targeted therapies. Key market players are collaborating with biotech firms and academia to accelerate the development of personalized medicine. The market is also witnessing a surge in funding from governmental and private sectors aimed at enhancing CNS treatment options, forecasting significant expansion through the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Central Nervous System Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Neurovascular Diseases
  • Hemorrhagic Stroke
  • Ischemic Stroke
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
• Mental Health
  • Epilepsy
  • Mood Disorders
  • Anxiety Disorders
  • Others
• Infectious Diseases
  • Meningitis
  • Encephalitis
  • Others
• Others

Global Central Nervous System Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Biologics
• Non-biologics

Global Central Nervous System Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Immunomodulatory Drugs
• Interferons
• Decarboxylase Inhibitors
• Dopamine Agonists
• Antidepressants
• Analgesics
• Others

Global Central Nervous System Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Central Nervous System Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations